{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:53:15Z","timestamp":1783601595910,"version":"3.55.0"},"reference-count":242,"publisher":"Bentham Science Publishers Ltd.","issue":"6","funder":[{"DOI":"10.13039\/501100004587","name":"Fondo de Investigaci\u00f3n Sanitaria, Instituto de Salud Carlos III, Spain","doi-asserted-by":"publisher","award":["PI15\/00303"],"award-info":[{"award-number":["PI15\/00303"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Fondo de Investigaci\u00f3n Sanitaria, Instituto de Salud Carlos III, Spain","doi-asserted-by":"publisher","award":["PI18\/00540"],"award-info":[{"award-number":["PI18\/00540"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Fondo de Investigaci\u00f3n Sanitaria, Instituto de Salud Carlos III, Spain","doi-asserted-by":"publisher","award":["RETICS RD16\/0006\/ 0004"],"award-info":[{"award-number":["RETICS RD16\/0006\/ 0004"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008432","name":"Junta de Extremadura, Spain","doi-asserted-by":"publisher","award":["IB16170"],"award-info":[{"award-number":["IB16170"]}],"id":[{"id":"10.13039\/501100008432","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008432","name":"Junta de Extremadura, Spain","doi-asserted-by":"publisher","award":["GR18145"],"award-info":[{"award-number":["GR18145"]}],"id":[{"id":"10.13039\/501100008432","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2020,6,22]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Essential Tremor (ET) is likely the most frequent movement disorder. In this review, we have summarized the current pharmacological options for the treatment of this disorder and discussed several future options derived from drugs tested in experimental models of ET or from neuropathological data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>A literature search was performed on the pharmacology of essential tremors using PubMed Database from 1966 to July 31, 2019.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>To date, the beta-blocker propranolol and the antiepileptic drug primidone are the drugs that have shown higher efficacy in the treatment of ET. Other drugs tested in ET patients have shown different degrees of efficacy or have not been useful.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Injections of botulinum toxin A could be useful in the treatment of some patients with ET refractory to pharmacotherapy. According to recent neurochemical data, drugs acting on the extrasynaptic GABAA receptors, the glutamatergic system or LINGO-1 could be interesting therapeutic options in the future.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1570159x18666200124145743","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T15:02:30Z","timestamp":1579878150000},"page":"518-537","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Current and Future Neuropharmacological Options for the Treatment of Essential Tremor"],"prefix":"10.2174","volume":"18","author":[{"given":"Hortensia","family":"Alonso-Navarro","sequence":"first","affiliation":[{"name":"Section of Neurology, Hospital Universitario del Sureste, Arganda del Rey, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Garc\u00eda-Mart\u00edn","sequence":"additional","affiliation":[{"name":"University Institute of Molecular Pathology Biomarkers, UNEx. ARADyAL Instituto de Salud Carlos III, Caceres, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.G.","family":"Ag\u00fandez","sequence":"additional","affiliation":[{"name":"University Institute of Molecular Pathology Biomarkers, UNEx. ARADyAL Instituto de Salud Carlos III, Caceres, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix J.","family":"Jim\u00e9nez-Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Section of Neurology, Hospital Universitario del Sureste, Arganda del Rey, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/ane.12148","volume":"128","author":"Jim\u00e9nez-Jim\u00e9nez F.J.","year":"2013","unstructured":"Jim\u00e9nez-Jim\u00e9nez F.J.; Alonso-Navarro H.; Garc\u00eda-Mart\u00edn E.; Lorenzo-Betancor O.; Pastor P.; Ag\u00fandez J.A.; Update on genetics of essential tremor. Acta Neurol Scand 2013,128(6),359-371","journal-title":"Acta Neurol Scand"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/B978-0-444-63233-3.00015-4","volume":"147","author":"Clark L.N.","year":"2018","unstructured":"Clark L.N.; Louis E.D.; Essential tremor. Handb Clin Neurol 2018,147,229-239","journal-title":"Handb Clin Neurol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000103646","volume":"58","author":"Jim\u00e9nez-Jim\u00e9nez F.J.","year":"2007","unstructured":"Jim\u00e9nez-Jim\u00e9nez F.J.; de Toledo-Heras M.; Alonso-Navarro H.; Ayuso-Peralta L.; Ar\u00e9valo-Serrano J.; Ballesteros-Barranco A.; Puertas I.; Jabbour-Wadih T.; Barcenilla B.; Environmental risk factors for essential tremor. Eur Neurol 2007,58(2),106-113","journal-title":"Eur Neurol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.2174\/0929867325666181112094330","volume":"27","author":"Jim\u00e9nez-Jim\u00e9nez F.J.","year":"2020","unstructured":"Jim\u00e9nez-Jim\u00e9nez F.J.; Alonso-Navarro H.; Garc\u00eda-Mart\u00edn E.; Ag\u00fandez J.A.G.; An update on the neurochemistry of essential tremor. Curr Med Chem 2020,27(10),1690-1710","journal-title":"Curr Med Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1212\/WNL.25.3.259","volume":"25","author":"Growdon J.H.","year":"1975","unstructured":"Growdon J.H.; Shahani B.T.; Young R.R.; The effect of alcohol on essential tremor. Neurology 1975,25(3),259-262","journal-title":"Neurology"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1212\/WNL.34.2.221","volume":"34","author":"Koller W.C.","year":"1984","unstructured":"Koller W.C.; Biary N.; Effect of alcohol on tremors: comparison with propranolol. Neurology 1984,34(2),221-222","journal-title":"Neurology"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/mds.10553","volume":"18","author":"Zeuner K.E.","year":"2003","unstructured":"Zeuner K.E.; Molloy F.M.; Shoge R.O.; Goldstein S.R.; Wesley R.; Hallett M.; Effect of ethanol on the central oscillator in essential tremor. Mov Disord 2003,18(11),1280-1285","journal-title":"Mov Disord"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1002\/mds.23846","volume":"26","author":"Knudsen K.","year":"2011","unstructured":"Knudsen K.; Lorenz D.; Deuschl G.; A clinical test for the alcohol sensitivity of essential tremor. Mov Disord 2011,26(12),2291-2295","journal-title":"Mov Disord"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2165\/00002018-200326070-00003","volume":"26","author":"Lyons K.E.","year":"2003","unstructured":"Lyons K.E.; Pahwa R.; Comella C.L.; Eisa M.S.; Elble R.J.; Fahn S.; Jankovic J.; Juncos J.L.; Koller W.C.; Ondo W.G.; Sethi K.D.; Stern M.B.; Tanner C.M.; Tintner R.; Watts R.L.; Benefits and risks of pharmacological treatments for essential tremor. Drug Saf 2003,26(7),461-481","journal-title":"Drug Saf"},{"key":"ref=10","author":"Jimenez-Jimenez F.J.","unstructured":"Jimenez-Jimenez F.J.; Puertas-Munoz I.; de Toledo-Heras M.; Neuroquimica y neurofarmacologia del temblor esencial. Neuroquimica y neurofarmacologia de los trastornos del movimiento. In: Jim\u00e9nez-Jim\u00e9nez, F.J. Luquin-Piudo, M.R. (eds.). Neurolog\u00eda, 2013, 18(Suppl. 3), 37-45."},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2174\/9781608057757113020007","volume":"Vol. 2","author":"Alonso-Navarro H.","year":"2013","unstructured":"Alonso-Navarro H.; Jimenez-Jimenez F.J.; Garcia-Martin E.; Agundez J.A.G.; Neurochemistry and Neuropharmacology of Essential Tremore-book) Frontiers in Clinical Drug Research - CNS and Neurological Disorders 2013,Vol. 2,110-142","journal-title":"Neurochemistry and Neuropharmacology of Essential Tremore-book) Frontiers in Clinical Drug Research - CNS and Neurological Disorders"},{"key":"ref=12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"Moher D.","year":"2009","unstructured":"Moher D.; Liberati A.; Tetzlaff J.; Altman D.G.; Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009,6(7)","journal-title":"PLoS Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/mds.27700","volume":"34","author":"Ferreira J.J.","year":"2019","unstructured":"Ferreira J.J.; Mestre T.A.; Lyons K.E.; Benito-Le\u00f3n J.; Tan E.K.; Abbruzzese G.; Hallett M.; Haubenberger D.; Elble R.; Deuschl G.; MDS evidence-based review of treatments for essential tremor. Mov Disord 2019,34(7),950-958","journal-title":"Mov Disord"},{"key":"ref=14","author":"Lang A.E.","unstructured":"Lang A.E.; Lees A.; Introduction.Management of Parkinson\u2019s disease: an evidence-based review In: Mov. Disord; Lang, A.R.; Lees, A., Eds.; 2002; 17, pp. (Suppl. 4)S1-S6"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"E199","DOI":"10.1152\/ajpendo.2001.280.2.E199","volume":"280","author":"Granneman J.G.","year":"2001","unstructured":"Granneman J.G.; The putative beta4-adrenergic receptor is a novel state of the beta1-adrenergic receptor. Am J Physiol Endocrinol Metab 2001,280(2),E199-E202","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=16","first-page":"984","volume":"107","author":"Murray T.J.","year":"1972","unstructured":"Murray T.J.; Treatment of essential tremor with propranolol. Can Med Assoc J 1972,107(10),984-986","journal-title":"Can Med Assoc J"},{"key":"ref=17","first-page":"66","volume":"96","author":"Winkler G.F.","year":"1971","unstructured":"Winkler G.F.; Young R.R.; The control of essential tremor by propranolol. Trans Am Neurol Assoc 1971,96,66-68","journal-title":"Trans Am Neurol Assoc"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(72)90431-X","volume":"1","author":"Pakkenberg H.","year":"1972","unstructured":"Pakkenberg H.; Propranolol in essential tremor. Lancet 1972,1,633","journal-title":"Lancet"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1600-0404.1973.tb01280.x","volume":"49","author":"Dupont E.","year":"1973","unstructured":"Dupont E.; Hansen H.J.; Dalby M.A.; Treatment of benign essential tremor with propranolol. A controlled clinical trial. Acta Neurol Scand 1973,49(1),75-84","journal-title":"Acta Neurol Scand"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1056\/NEJM197405022901802","volume":"290","author":"Winkler G.F.","year":"1974","unstructured":"Winkler G.F.; Young R.R.; Efficacy of chronic propranolol therapy in action tremors of the familial, senile or essential varieties. N Engl J Med 1974,290(18),984-988","journal-title":"N Engl J Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1212\/WNL.25.11.1041","volume":"25","author":"Tolosa E.S.","year":"1975","unstructured":"Tolosa E.S.; Loewenson R.B.; Essential tremor: treatment with propranolol. Neurology 1975,25(11),1041-1044","journal-title":"Neurology"},{"key":"ref=22","first-page":"267","volume":"101","author":"McAllister R.G.","year":"1976","unstructured":"McAllister R.G.; Markesbery W.R.; Ware R.W.; Howell S.M.; Suppression of essential tremor by propranolol: correlation of effect with intensity of beta-adrenergic blockade. Trans Am Neurol Assoc 1976,101,267-269","journal-title":"Trans Am Neurol Assoc"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1212\/WNL.26.1.27","volume":"26","author":"Ter\u00e4v\u00e4inen H.","year":"1976","unstructured":"Ter\u00e4v\u00e4inen H.; Fogelholm R.; Larsen A.; Effect of propranolol on essential tremor. Neurology 1976,26(1),27-30","journal-title":"Neurology"},{"key":"ref=24","first-page":"892","volume":"115","author":"Murray T.J.","year":"1976","unstructured":"Murray T.J.; Long-term therapy of essential tremor with propranolol. Can Med Assoc J 1976,115(9),892-894","journal-title":"Can Med Assoc J"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/ana.410010210","volume":"1","author":"McAllister R.G.","year":"1977","unstructured":"McAllister R.G.; Markesbery W.R.; Ware R.W.; Howell S.M.; Suppression of essential tremor by propranolol: correlation of effect with drug plasma levels and intensity of beta-adrenergic blockade. Ann Neurol 1977,1(2),160-166","journal-title":"Ann Neurol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1212\/WNL.27.5.439","volume":"27","author":"Teravainen H.","year":"1977","unstructured":"Teravainen H.; Larsen A.; Fogelholm R.; Comparison between the effects of pindolol and propranolol on essential tremor. Neurology 1977,27(5),439-442","journal-title":"Neurology"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"419P","DOI":"10.1111\/j.1365-2125.1979.tb00964.x","volume":"7","author":"Jefferson D.","year":"1979","unstructured":"Jefferson D.; Jenner P.; Marsden C.D.; Relationship between plasma propranolol levels and the clinical suppression of essential tremor [proceedings]. Br J Clin Pharmacol 1979,7(4),419P-420P","journal-title":"Br J Clin Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/jnnp.42.9.831","volume":"42","author":"Jefferson D.","year":"1979","unstructured":"Jefferson D.; Jenner P.; Marsden C.D.; Relationship between plasma propranolol concentration and relief of essential tremor. J Neurol Neurosurg Psychiatry 1979,42(9),831-837","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/ana.410090110","volume":"9","author":"S\u00f8rensen P.S.","year":"1981","unstructured":"S\u00f8rensen P.S.; Paulson O.B.; Steiness E.; Jansen E.C.; Essential tremor treated with propranolol: lack of correlation between clinical effect and plasma propranolol levels. Ann Neurol 1981,9(1),53-57","journal-title":"Ann Neurol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/ana.410130210","volume":"13","author":"Calzetti S.","year":"1983","unstructured":"Calzetti S.; Findley L.J.; Gresty M.A.; Perucca E.; Richens A.; Effect of a single oral dose of propranolol on essential tremor: a double-blind controlled study. Ann Neurol 1983,13(2),165-171","journal-title":"Ann Neurol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1136\/jnnp.46.5.393","volume":"46","author":"Calzetti S.","year":"1983","unstructured":"Calzetti S.; Findley L.J.; Perucca E.; Richens A.; The response of essential tremor to propranolol: evaluation of clinical variables governing its efficacy on prolonged administration. J Neurol Neurosurg Psychiatry 1983,46(5),393-398","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1212\/WNL.35.10.1494","volume":"35","author":"Koller W.C.","year":"1985","unstructured":"Koller W.C.; Royse V.L.; Time course of a single oral dose of propranolol in essential tremor. Neurology 1985,35(10),1494-1498","journal-title":"Neurology"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/archneur.1986.00520010038018","volume":"43","author":"Koller W.C.","year":"1986","unstructured":"Koller W.C.; Dose-response relationship of propranolol in the treatment of essential tremor. Arch Neurol 1986,43(1),42-43","journal-title":"Arch Neurol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1600-0404.1990.tb00982.x","volume":"81","author":"Calzetti S.","year":"1990","unstructured":"Calzetti S.; Sasso E.; Baratti M.; Fava R.; Clinical and computer-based assessment of long-term therapeutic efficacy of propranolol in essential tremor. Acta Neurol Scand 1990,81(5),392-396","journal-title":"Acta Neurol Scand"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1212\/WNL.35.1.108","volume":"35","author":"Koller W.C.","year":"1985","unstructured":"Koller W.C.; Long-acting propranolol in essential tremor. Neurology 1985,35(1),108-110","journal-title":"Neurology"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/jnnp.51.3.379","volume":"51","author":"Cleeves L.","year":"1988","unstructured":"Cleeves L.; Findley L.J.; Propranolol and propranolol-LA in essential tremor: a double blind comparative study. J Neurol Neurosurg Psychiatry 1988,51(3),379-384","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1590\/S0004-282X2004000100015","volume":"62","author":"Troiano A.R.","year":"2004","unstructured":"Troiano A.R.; Teive H.A.; Fabiani G.B.; Zavala J.A.; S\u00e1 D.S.; Germiniani F.M.; Camargo C.H.; Werneck L.C.; Uso do propranolol de a\u00e7\u00e3o prolongada em 40 pacientes com tremor essencial e virgens de tratamento: um ensaio cl\u00ednico n\u00e3o controlado. Arq Neuropsiquiatr 2004,62(1),86-90","journal-title":"Arq Neuropsiquiatr"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1212\/WNL.34.8.1077","volume":"34","author":"Koller W.C.","year":"1984","unstructured":"Koller W.C.; Propranolol therapy for essential tremor of the head. Neurology 1984,34(8),1077-1079","journal-title":"Neurology"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/00002826-199212000-00004","volume":"15","author":"Calzetti S.","year":"1992","unstructured":"Calzetti S.; Sasso E.; Negrotti A.; Baratti M.; Fava R.; Effect of propranolol in head tremor: quantitative study following single-dose and sustained drug administration. Clin Neuropharmacol 1992,15(6),470-476","journal-title":"Clin Neuropharmacol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1007\/s00415-018-9052-z","volume":"265","author":"Paparella G.","year":"2018","unstructured":"Paparella G.; Ferrazzano G.; Cannavacciuolo A.; Cogliati Dezza F.; Fabbrini G.; Bologna M.; Berardelli A.; Differential effects of propranolol on head and upper limb tremor in patients with essential tremor and dystonia. J Neurol 2018,265(11),2695-2703","journal-title":"J Neurol"},{"key":"ref=41","author":"Alonso-Navarro H.","unstructured":"Alonso-Navarro H.; Rubio Ll.; Benito-Leon J.; Vazquez Rodriguez A.; Jimenez-Jimenez F.J.; Temblor esencial .Tratado de los Trastornos del Movimiento. 2nd Edition. Barcelona, Viguera Editores S.L, 2008; pp. 829-882;"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3348\/kjr.2015.16.5.967","volume":"16","author":"Song I.U.","year":"2015","unstructured":"Song I.U.; Ha S.W.; Yang Y.S.; Chung Y.A.; Differences in Regional Glucose Metabolism of the Brain Measured with F-18-FDG-PET in Patients with Essential Tremor According to Their Response to Beta-Blockers. Korean J Radiol 2015,16(5),967-972","journal-title":"Korean J Radiol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1212\/WNL.0b013e318236f0fd","volume":"77","author":"Zesiewicz T.A.","year":"2011","unstructured":"Zesiewicz T.A.; Elble R.J.; Louis E.D.; Gronseth G.S.; Ondo W.G.; Dewey R.B.; Okun M.S.; Sullivan K.L.; Weiner W.J.; Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology 2011,77(19),1752-1755","journal-title":"Neurology"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s00415-012-6628-x","volume":"260","author":"Zappia M.","year":"2013","unstructured":"Zappia M.; Albanese A.; Bruno E.; Colosimo C.; Filippini G.; Martinelli P.; Nicoletti A.; Quattrocchi G.; Abbruzzese G.; Berardelli A.; Allegra R.; Aniello M.S.; Elia A.E.; Martino D.; Murgia D.; Picillo M.; Squintani G.; Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. J Neurol 2013,260(3),714-740","journal-title":"J Neurol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJM197908093010617","volume":"301","author":"Britt C.W.","year":"1979","unstructured":"Britt C.W.; Peters B.H.; Metoprolol for essential tremor. N Engl J Med 1979,301(6),331","journal-title":"N Engl J Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/S0140-6736(80)91474-9","volume":"1","author":"Ljung O.","year":"1980","unstructured":"Ljung O.; Metoprolol in essential tremor. Lancet 1980,1(8176),1032","journal-title":"Lancet"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1056\/NEJM197909203011215","volume":"301","author":"Riley T.","year":"1979","unstructured":"Riley T.; Pleet A.B.; Metoprolol tartrate for essential tremor. N Engl J Med 1979,301(12),663","journal-title":"N Engl J Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/archneur.1980.00500580092022","volume":"37","author":"Newman R.P.","year":"1980","unstructured":"Newman R.P.; Jacobs L.; Metoprolol in essential tremor. Arch Neurol 1980,37(9),596-597","journal-title":"Arch Neurol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1136\/jnnp.45.10.893","volume":"45","author":"Calzetti S.","year":"1982","unstructured":"Calzetti S.; Findley L.J.; Perucca E.; Richens A.; Controlled study of metoprolol and propranolol during prolonged administration in patients with essential tremor. J Neurol Neurosurg Psychiatry 1982,45(10),893-897","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1136\/jnnp.44.9.814","volume":"44","author":"Calzetti S.","year":"1981","unstructured":"Calzetti S.; Findley L.J.; Gresty M.A.; Perucca E.; Richens A.; Metoprolol and propranolol in essential tremor: a double-blind, controlled study. J Neurol Neurosurg Psychiatry 1981,44(9),814-819","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=51","first-page":"247","volume":"37","author":"Larsen T.A.","year":"1983","unstructured":"Larsen T.A.; Ter\u00e4v\u00e4inen H.; Beta 1 versus nonselective blockade in therapy of essential tremor. Adv Neurol 1983,37,247-251","journal-title":"Adv Neurol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/jnnp.46.8.710","volume":"46","author":"Leigh P.N.","year":"1983","unstructured":"Leigh P.N.; Jefferson D.; Twomey A.; Marsden C.D.; Beta-adrenoreceptor mechanisms in essential tremor; a double-blind placebo controlled trial of metoprolol, sotalol and atenolol. J Neurol Neurosurg Psychiatry 1983,46(8),710-715","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1001\/archneur.1984.04050140069026","volume":"41","author":"Koller W.C.","year":"1984","unstructured":"Koller W.C.; Biary N.; Metoprolol compared with propranolol in the treatment of essential tremor. Arch Neurol 1984,41(2),171-172","journal-title":"Arch Neurol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/clpt.1984.182","volume":"36","author":"Gengo F.M.","year":"1984","unstructured":"Gengo F.M.; Ulatowski J.A.; McHugh W.B.; Metoprolol and alpha-hydroxymetoprolol concentrations and reduction in essential tremor. Clin Pharmacol Ther 1984,36(3),320-325","journal-title":"Clin Pharmacol Ther"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1136\/jnnp.44.8.677","volume":"44","author":"Dietrichson P.","year":"1981","unstructured":"Dietrichson P.; Espen E.; Effects of timolol and atenolol on benign essential tremor: placebo-controlled studies based on quantitative tremor recording. J Neurol Neurosurg Psychiatry 1981,44(8),677-683","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1600-0404.1982.tb03141.x","volume":"66","author":"Larsen T.A.","year":"1982","unstructured":"Larsen T.A.; Ter\u00e4v\u00e4inen H.; Calne D.B.; Atenolol vs. propranolol in essential tremor. A controlled, quantitative study. Acta Neurol Scand 1982,66(5),547-554","journal-title":"Acta Neurol Scand"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1212\/WNL.33.8.1074","volume":"33","author":"Koller W.C.","year":"1983","unstructured":"Koller W.C.; Alcoholism in essential tremor. Neurology 1983,33(8),1074-1076","journal-title":"Neurology"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/BF00314194","volume":"235","author":"Ogawa N.","year":"1987","unstructured":"Ogawa N.; Takayama H.; Yamamoto M.; Comparative studies on the effects of beta-adrenergic blockers in essential tremor. J Neurol 1987,235(1),31-33","journal-title":"J Neurol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S1353-8020(03)00029-4","volume":"9","author":"Lee K.S.","year":"2003","unstructured":"Lee K.S.; Kim J.S.; Kim J.W.; Lee W.Y.; Jeon B.S.; Kim D.; A multicenter randomized crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor. Parkinsonism Relat Disord 2003,9(6),341-347","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1212\/WNL.38.4.650","volume":"38","author":"Kuroda Y.","year":"1988","unstructured":"Kuroda Y.; Kakigi R.; Shibasaki H.; Treatment of essential tremor with arotinolol. Neurology 1988,38(4),650-652","journal-title":"Neurology"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2169\/internalmedicine.35.861","volume":"35","author":"Yoshii F.","year":"1996","unstructured":"Yoshii F.; Shinohara Y.; Takeoka T.; Kitagawa Y.; Akiyama K.; Yazaki K.; Treatment of essential and parkinsonian tremor with nipradilol. Intern Med 1996,35(11),861-865","journal-title":"Intern Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/00002826-198710000-00007","volume":"10","author":"Koller W.","year":"1987","unstructured":"Koller W.; Orebaugh C.; Lawson L.; Potempa K.; Pindolol-induced tremor. Clin Neuropharmacol 1987,10(5),449-452","journal-title":"Clin Neuropharmacol"},{"key":"ref=63","doi-asserted-by":"publisher","author":"Elble R.J.","unstructured":"Elble R.J.; Beta-blockers in movement disorders.The encyclopedia of movement disorders Elsevier Ltd.: Oxford.; UK, 2010; 1, pp. 135-136.","DOI":"10.1016\/B978-0-12-374105-9.00307-5"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/WNF.0000000000000127","volume":"39","author":"Louis E.D.","year":"2016","unstructured":"Louis E.D.; Hernandez N.; Dyke J.P.; Ma R.; Dydak U.; Effect of primidone on dentate nucleus \u03b3-aminobutyric acid concentration in patients with essential tremor. Clin Neuropharmacol 2016,39(1),24-28","journal-title":"Clin Neuropharmacol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1136\/bmj.282.6259.178","volume":"282","author":"O\u2019Brien M.D.","year":"1981","unstructured":"O\u2019Brien M.D.; Upton A.R.; Toseland P.A.; Benign familial tremor treated with primidone. Br Med J (Clin Res Ed) 1981,282(6259),178-180","journal-title":"Br Med J (Clin Res Ed)"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1136\/jnnp.44.7.650","volume":"44","author":"Chakrabarti A.","year":"1981","unstructured":"Chakrabarti A.; Pearce J.M.; Essential tremor: response to primidone. J Neurol Neurosurg Psychiatry 1981,44(7),650","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1136\/bmj.285.6342.608","volume":"285","author":"Findley L.J.","year":"1982","unstructured":"Findley L.J.; Calzetti S.; Double-blind controlled study of primidone in essential tremor: preliminary results. Br Med J (Clin Res Ed) 1982,285(6342),608","journal-title":"Br Med J (Clin Res Ed)"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1136\/jnnp.48.9.911","volume":"48","author":"Findley L.J.","year":"1985","unstructured":"Findley L.J.; Cleeves L.; Calzetti S.; Primidone in essential tremor of the hands and head: a double blind controlled clinical study. J Neurol Neurosurg Psychiatry 1985,48(9),911-915","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1212\/WNL.36.1.121","volume":"36","author":"Koller W.C.","year":"1986","unstructured":"Koller W.C.; Royse V.L.; Efficacy of primidone in essential tremor. Neurology 1986,36(1),121-124","journal-title":"Neurology"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/BF00314310","volume":"235","author":"Seyfert S.","year":"1988","unstructured":"Seyfert S.; Hon\u00e9 A.; Holl G.; Primidone and essential tremor. J Neurol 1988,235(3),168-170","journal-title":"J Neurol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/jnnp.49.1.64","volume":"49","author":"Gorman W.P.","year":"1986","unstructured":"Gorman W.P.; Cooper R.; Pocock P.; Campbell M.J.; A comparison of primidone, propranolol, and placebo in essential tremor, using quantitative analysis. J Neurol Neurosurg Psychiatry 1986,49(1),64-68","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1600-0404.1987.tb05455.x","volume":"75","author":"Dietrichson P.","year":"1987","unstructured":"Dietrichson P.; Espen E.; Primidone and propranolol in essential tremor: a study based on quantitative tremor recording and plasma anticonvulsant levels. Acta Neurol Scand 1987,75(5),332-340","journal-title":"Acta Neurol Scand"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1212\/WNL.39.12.1587","volume":"39","author":"Koller W.C.","year":"1989","unstructured":"Koller W.C.; Vetere-Overfield B.; Acute and chronic effects of propranolol and primidone in essential tremor. Neurology 1989,39(12),1587-1588","journal-title":"Neurology"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1001\/jamaoto.2015.2849","volume":"142","author":"Nida A.","year":"2016","unstructured":"Nida A.; Alston J.; Schweinfurth J.; Primidone therapy for essential vocal tremor. JAMA Otolaryngol Head Neck Surg 2016,142(2),117-121","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00002826-199002000-00007","volume":"13","author":"Sasso E.","year":"1990","unstructured":"Sasso E.; Perucca E.; Fava R.; Calzetti S.; Primidone in the long-term treatment of essential tremor: a prospective study with computerized quantitative analysis. Clin Neuropharmacol 1990,13(1),67-76","journal-title":"Clin Neuropharmacol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1212\/WNL.41.4.602","volume":"41","author":"Sasso E.","year":"1991","unstructured":"Sasso E.; Perucca E.; Negrotti A.; Calzetti S.; Acute tolerance to the tremorolytic effect of primidone. Neurology 1991,41(4),602-603","journal-title":"Neurology"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1212\/WNL.38.5.808","volume":"38","author":"Sasso E.","year":"1988","unstructured":"Sasso E.; Perucca E.; Calzetti S.; Double-blind comparison of primidone and phenobarbital in essential tremor. Neurology 1988,38(5),808-810","journal-title":"Neurology"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/mds.870060112","volume":"6","author":"Sasso E.","year":"1991","unstructured":"Sasso E.; Perucca E.; Fava R.; Calzetti S.; Quantitative comparison of barbiturates in essential hand and head tremor. Mov Disord 1991,6(1),65-68","journal-title":"Mov Disord"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1136\/jnnp.44.10.932","volume":"44","author":"Calzetti S.","year":"1981","unstructured":"Calzetti S.; Findley L.J.; Pisani F.; Richens A.; Phenylethylmalonamide in essential tremor. A double-blind controlled study. J Neurol Neurosurg Psychiatry 1981,44(10),932-934","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1212\/WNL.33.3.296","volume":"33","author":"Baruzzi A.","year":"1983","unstructured":"Baruzzi A.; Procaccianti G.; Martinelli P.; Riva R.; Denoth F.; Montanaro N.; Lugaresi E.; Phenobarbital and propranolol in essential tremor: a double-blind controlled clinical trial. Neurology 1983,33(3),296-300","journal-title":"Neurology"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1212\/WNL.35.12.1784","volume":"35","author":"Findley L.J.","year":"1985","unstructured":"Findley L.J.; Cleeves L.; Phenobarbitone in essential tremor. Neurology 1985,35(12),1784-1787","journal-title":"Neurology"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1353-8020(03)00070-1","volume":"10","author":"Serrano-Due\u00f1as M.","year":"2003","unstructured":"Serrano-Due\u00f1as M.; Use of primidone in low doses (250 mg\/day) versus high doses (750 mg\/day) in the management of essential tremor. Double-blind comparative study with one-year follow-up. Parkinsonism Relat Disord 2003,10(1),29-33","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/mds.10083","volume":"17","author":"O\u2019Suilleabhain P.","year":"2002","unstructured":"O\u2019Suilleabhain P.; Dewey R.B.; Randomized trial comparing primidone initiation schedules for treating essential tremor. Mov Disord 2002,17(2),382-386","journal-title":"Mov Disord"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000095702","volume":"56","author":"Alonso-Navarro H.","year":"2006","unstructured":"Alonso-Navarro H.; Mart\u00ednez C.; Garc\u00eda-Mart\u00edn E.; Benito-Le\u00f3n J.; Garc\u00eda-Ferrer I.; V\u00e1zquez-Torres P.; Puertas I.; L\u00f3pez-Alburquerque T.; Ag\u00fandez J.A.; Jim\u00e9nez-Jim\u00e9nez F.J.; CYP2C19 polymorphysm and risk for essential tremor. Eur Neurol 2006,56,119-123","journal-title":"Eur Neurol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/BF02685892","volume":"9","author":"Mart\u00ednez C.","year":"2007","unstructured":"Mart\u00ednez C.; Garc\u00eda-Mart\u00edn E.; Alonso-Navarro H.; Jim\u00e9nez-Jim\u00e9nez F.J.; Benito-Le\u00f3n J.; Garc\u00eda-Ferrer I.; V\u00e1zquez-Torres P.; Puertas I.; Zurdo J.M.; L\u00f3pez-Alburquerque T.; Ag\u00fandez J.A.; Changes at the CYP2C locus and disruption of CYP2C8\/9 linkage disequilibrium in patients with essential tremor. Neuromolecular Med 2007,9(2),195-204","journal-title":"Neuromolecular Med"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/mds.21321","volume":"22","author":"Melmed C.","year":"2007","unstructured":"Melmed C.; Moros D.; Rutman H.; Treatment of essential tremor with the barbiturate T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid). Mov Disord 2007,22(5),723-727","journal-title":"Mov Disord"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.parkreldis.2012.11.014","volume":"19","author":"Hadj Tahar A.","year":"2013","unstructured":"Hadj Tahar A.; Chuang R.; Steeves T.; Jog M.; Lang A.; Grimes D.; Efficacy and safety of T2000 in older patients with essential tremor. Parkinsonism Relat Disord 2013,19(4),485-486","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1001\/archneur.56.4.475","volume":"56","author":"Gironell A.","year":"1999","unstructured":"Gironell A.; Kulisevsky J.; Barbanoj M.; L\u00f3pez-Villegas D.; Hern\u00e1ndez G.; Pascual-Sedano B.; A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. Arch Neurol 1999,56(4),475-480","journal-title":"Arch Neurol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"322","DOI":"10.33588\/rn.3604.2002313","volume":"36","author":"L\u00f3pez del Val L.J.","year":"2003","unstructured":"L\u00f3pez del Val L.J.; Santos S.; Gabapentina en el tratamiento del temblor. Rev Neurol 2003,36(4),322-326","journal-title":"Rev Neurol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/1531-8257(200007)15:4<678:AID-MDS1012>3.0.CO;2-0","volume":"15","author":"Ondo W.","year":"2000","unstructured":"Ondo W.; Hunter C.; Vuong K.D.; Schwartz K.; Jankovic J.; Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord 2000,15(4),678-682","journal-title":"Mov Disord"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/mds.870130315","volume":"13","author":"Pahwa R.","year":"1998","unstructured":"Pahwa R.; Lyons K.; Hubble J.P.; Busenbark K.; Rienerth J.D.; Pahwa A.; Koller W.C.; Double-blind controlled trial of gabapentin in essential tremor. Mov Disord 1998,13(3),465-467","journal-title":"Mov Disord"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"798","DOI":"10.33588\/rn.3108.2000111","volume":"31","author":"Padilla F.","year":"2000","unstructured":"Padilla F.; Berthier M.L.; Campos-Arillo V.M.; Temblor esencial de la voz y tratamiento con gabapentina. Rev Neurol 2000,31(8),798","journal-title":"Rev Neurol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1002\/mds.22094","volume":"23","author":"Gironell A.","year":"2008","unstructured":"Gironell A.; Mart\u00ednez-Corral M.; Pagonabarraga X.; Kulisevsky J.; Tiagabine for essential tremor: an open-label trial. Mov Disord 2008,23(13),1955-1956","journal-title":"Mov Disord"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/1531-8249(200006)47:6<837:AID-ANA24>3.0.CO;2-2","volume":"47","author":"G\u00e1lvez-Jim\u00e9nez N.","year":"2000","unstructured":"G\u00e1lvez-Jim\u00e9nez N.; Hargreave M.; Topiramate and essential tremor. Ann Neurol 2000,47(6),837-838","journal-title":"Ann Neurol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/00002826-200311000-00006","volume":"26","author":"Gatto E.M.","year":"2003","unstructured":"Gatto E.M.; Roca M.C.; Raina G.; Micheli F.; Low doses of topiramate are effective in essential tremor: a report of three cases. Clin Neuropharmacol 2003,26(6),294-296","journal-title":"Clin Neuropharmacol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1212\/WNL.59.1.132","volume":"59","author":"Connor G.S.","year":"2002","unstructured":"Connor G.S.; A double-blind placebo-controlled trial of topiramate treatment for essential tremor. Neurology 2002,59(1),132-134","journal-title":"Neurology"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1212\/01.wnl.0000200779.03748.0f","volume":"66","author":"Ondo W.G.","year":"2006","unstructured":"Ondo W.G.; Jankovic J.; Connor G.S.; Pahwa R.; Elble R.; Stacy M.A.; Koller W.C.; Schwarzman L.; Wu S.C.; Hulihan J.F.; Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology 2006,66(5),672-677","journal-title":"Neurology"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/WNF.0b013e3180d09969","volume":"31","author":"Connor G.S.","year":"2008","unstructured":"Connor G.S.; Edwards K.; Tarsy D.; Topiramate in essential tremor: findings from double-blind, placebo-controlled, crossover trials. Clin Neuropharmacol 2008,31(2),97-103","journal-title":"Clin Neuropharmacol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/00002826-200603000-00007","volume":"29","author":"Frima N.","year":"2006","unstructured":"Frima N.; Gr\u00fcnewald R.A.; A double-blind, placebo-controlled, crossover trial of topiramate in essential tremor. Clin Neuropharmacol 2006,29(2),94-96","journal-title":"Clin Neuropharmacol"},{"key":"ref=100","first-page":"39","volume":"108","author":"Zalialova Z.A.","year":"2008","unstructured":"Zalialova Z.A.; Latypova G.R.; [Topiramate in the treatment of essential tremor]. Zh Nevrol Psikhiatr Im S S Korsakova 2008,108(11),39-42","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref=101","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001809","volume":"94","author":"Chang K.H.","year":"2015","unstructured":"Chang K.H.; Wang S.H.; Chi C.C.; Efficacy and safety of topiramate for essential tremor: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2015,94(43)","journal-title":"Medicine (Baltimore)"},{"key":"ref=102","author":"Bruno E.","unstructured":"Bruno E.; Nicoletti A.; Quattrocchi G.; Allegra R.; Filippini G.; Colosimo C.; Zappia M.; Topiramate for essential tremor Cochrane Database Syst Rev, 2017, 4CD009683","journal-title":"Topiramate for essential tremor Cochrane Database Syst Rev, 2017, 4CD009683"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/01.WNF.0000220823.80640.44","volume":"29","author":"Zesiewicz T.A.","year":"2006","unstructured":"Zesiewicz T.A.; Tullidge A.; Tidwell J.; Sullivan K.L.; Hauser R.A.; Topiramate-induced psychosis in patients with essential tremor: report of 2 cases. Clin Neuropharmacol 2006,29(3),168-169","journal-title":"Clin Neuropharmacol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/01.WNF.0000220825.65393.93","volume":"29","author":"Alonso-Navarro H.","year":"2006","unstructured":"Alonso-Navarro H.; Jim\u00e9nez-Jim\u00e9nez F.J.; Reversible tremor, myoclonus, and fasciculations associated with topiramate use for migraine. Clin Neuropharmacol 2006,29(3),157-159","journal-title":"Clin Neuropharmacol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/mds.20147","volume":"19","author":"Handforth A.","year":"2004","unstructured":"Handforth A.; Martin F.C.; Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor. Mov Disord 2004,19(10),1215-1221","journal-title":"Mov Disord"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1212\/01.WNL.0000154596.21335.2E","volume":"64","author":"Bushara K.O.","year":"2005","unstructured":"Bushara K.O.; Malik T.; Exconde R.E.; The effect of levetiracetam on essential tremor. Neurology 2005,64(6),1078-1080","journal-title":"Neurology"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/00002826-200411000-00004","volume":"27","author":"Ondo W.G.","year":"2004","unstructured":"Ondo W.G.; Jim\u00e9nez J.E.; Vuong K.D.; Jankovic J.; An open-label pilot study of levetiracetam for essential tremor. Clin Neuropharmacol 2004,27(6),274-277","journal-title":"Clin Neuropharmacol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/mds.20437","volume":"20","author":"Sullivan K.L.","year":"2005","unstructured":"Sullivan K.L.; Hauser R.A.; Zesiewicz T.A.; Levetiracetam for the treatment of essential tremor. Mov Disord 2005,20(5),640","journal-title":"Mov Disord"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"134","DOI":"10.33588\/rn.4503.2006227","volume":"45","author":"Sanz-Cartagena P.","year":"2007","unstructured":"Sanz-Cartagena P.; Fossas P.; Floriach-Robert M.; Serra-Prat M.; Cano A.; Palomeras E.; Eficacia y tolerabilidad del levetiracetam en pacientes con temblor esencial: datos de un ensayo abierto de 11 semanas de seguimiento. Rev Neurol 2007,45(3),134-136","journal-title":"Rev Neurol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/WNF.0b013E31807A32C6","volume":"30","author":"Elble R.J.","year":"2007","unstructured":"Elble R.J.; Lyons K.E.; Pahwa R.; Levetiracetam is not effective for essential tremor. Clin Neuropharmacol 2007,30(6),350-356","journal-title":"Clin Neuropharmacol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.neuropharm.2010.05.012","volume":"59","author":"Handforth A.","year":"2010","unstructured":"Handforth A.; Homanics G.E.; Covey D.F.; Krishnan K.; Lee J.Y.; Sakimura K.; Martin F.C.; Quesada A.; T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor. Neuropharmacology 2010,59(6),380-387","journal-title":"Neuropharmacology"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.parkreldis.2004.09.004","volume":"11","author":"Morita S.","year":"2005","unstructured":"Morita S.; Miwa H.; Kondo T.; Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. Parkinsonism Relat Disord 2005,11(2),101-103","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1002\/mds.21717","volume":"22","author":"Bermejo P.E.","year":"2007","unstructured":"Bermejo P.E.; Zonisamide in patients with essential tremor and Parkinson\u2019s disease. Mov Disord 2007,22(14),2137-2138","journal-title":"Mov Disord"},{"key":"ref=114","first-page":"139","volume":"46","author":"Bermejo P.E.","year":"2008","unstructured":"Bermejo P.E.; Ruiz-Huete C.; Dorado R.; Anciones B.; Zonisamida en el temblor esencial refractario. Rev Neurol 2008,46(3),139-142","journal-title":"Rev Neurol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/mds.22418","volume":"24","author":"Handforth A.","year":"2009","unstructured":"Handforth A.; Martin F.C.; Kang G.A.; Vanek Z.; Zonisamide for essential tremor: an evaluator-blinded study. Mov Disord 2009,24(3),437-440","journal-title":"Mov Disord"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/mds.21282","volume":"22","author":"Zesiewicz T.A.","year":"2007","unstructured":"Zesiewicz T.A.; Ward C.L.; Hauser R.A.; Sanchez-Ramos J.; Staffetti J.F.; Sullivan K.L.; A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. Mov Disord 2007,22(2),279-282","journal-title":"Mov Disord"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/WNF.0b013e318074dd4f","volume":"30","author":"Ondo W.G.","year":"2007","unstructured":"Ondo W.G.; Zonisamide for essential tremor. Clin Neuropharmacol 2007,30(6),345-349","journal-title":"Clin Neuropharmacol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/j.1468-1331.2008.02296.x","volume":"15","author":"Song I.U.","year":"2008","unstructured":"Song I.U.; Kim J.S.; Lee S.B.; Ryu S.Y.; An J.Y.; Kim H.T.; Kim Y.I.; Lee K.S.; Effects of zonisamide on isolated head tremor. Eur J Neurol 2008,15(11),1212-1215","journal-title":"Eur J Neurol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/01.jcp.0000227350.44664.50","volume":"26","author":"Sullivan K.L.","year":"2006","unstructured":"Sullivan K.L.; Ward C.L.; Zesiewicz T.A.; Zonisamide-induced mania in an essential tremor patient. J Clin Psychopharmacol 2006,26(4),439-440","journal-title":"J Clin Psychopharmacol"},{"key":"ref=120","author":"Bruno E.","unstructured":"Bruno E.; Nicoletti A.; Filippini G.; Quattrocchi G.; Colosimo C.; Zappia M.; Zonisamide for essential tremor Cochrane Database Syst Rev, 2017, 8CD009684","journal-title":"Zonisamide for essential tremor Cochrane Database Syst Rev, 2017, 8CD009684"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/mds.21211","volume":"22","author":"Zesiewicz T.A.","year":"2007","unstructured":"Zesiewicz T.A.; Ward C.L.; Hauser R.A.; Pease Campbell J.A.; Sullivan K.L.; Pregabalin (Lyrica) in the treatment of essential tremor. Mov Disord 2007,22(1),139-141","journal-title":"Mov Disord"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/mds.21629","volume":"22","author":"Zesiewicz T.A.","year":"2007","unstructured":"Zesiewicz T.A.; Ward C.L.; Hauser R.A.; Salemi J.L.; Siraj S.; Wilson M.C.; Sullivan K.L.; A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor. Mov Disord 2007,22(11),1660-1663","journal-title":"Mov Disord"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jns.2009.06.044","volume":"285","author":"Ferrara J.M.","year":"2009","unstructured":"Ferrara J.M.; Kenney C.; Davidson A.L.; Shinawi L.; Kissel A.M.; Jankovic J.; Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial. J Neurol Sci 2009,285(1-2),195-197","journal-title":"J Neurol Sci"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/mds.25264","volume":"28","author":"Zesiewicz T.A.","year":"2013","unstructured":"Zesiewicz T.A.; Sullivan K.L.; Hinson V.; Stover N.P.; Fang J.; Jahan I.; Miller A.; Carranza M.A.; Elble R.; Multisite, double-blind, randomized, controlled study of pregabalin for essential tremor. Mov Disord 2013,28(2),249-250","journal-title":"Mov Disord"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejphar.2008.06.038","volume":"589","author":"St\u00f6hr T.","year":"2008","unstructured":"St\u00f6hr T.; Lekieffre D.; Freitag J.; Lacosamide, the new anticonvulsant, effectively reduces harmaline-induced tremors in rats. Eur J Pharmacol 2008,589(1-3),114-116","journal-title":"Eur J Pharmacol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/mds.23296","volume":"26","author":"Gironell A.","year":"2011","unstructured":"Gironell A.; Pagonabarraga J.; Pascual-Sedano B.; Kulisevsky J.; Lacosamide, another therapeutic failure in essential tremor: an open-label trial. Mov Disord 2011,26(1),183-184","journal-title":"Mov Disord"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"378","DOI":"10.5334\/tohm.306","volume":"6","author":"Gironell A.","year":"2016","unstructured":"Gironell A.; Marin-Lahoz J.; Ethosuximide for essential tremor: An open-label trial. Tremor Other Hyperkinet Mov (N Y) 2016,6,378","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.parkreldis.2018.10.010","volume":"60","author":"Gironell A.","year":"2019","unstructured":"Gironell A.; Pascual-Sedano B.; Mar\u00edn-Lahoz J.; Perampanel, a new hope for Essential tremor: An open label trial. Parkinsonism Relat Disord 2019,60,171-172","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1345\/aph.1H131","volume":"40","author":"Raj V.","year":"2006","unstructured":"Raj V.; Landess J.S.; Martin P.R.; Oxcarbazepine use in essential tremor. Ann Pharmacother 2006,40(10),1876-1879","journal-title":"Ann Pharmacother"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/mds.22872","volume":"25","author":"Elble R.J.","year":"2010","unstructured":"Elble R.J.; Biondi D.M.; Ascher S.; Wiegand F.; Hulihan J.; Carisbamate in essential tremor: brief report of a proof of concept study. Mov Disord 2010,25(5),634-638","journal-title":"Mov Disord"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000116142","volume":"27","author":"Topaktas S.","year":"1987","unstructured":"Topaktas S.; Onur R.; Dalkara T.; Calcium channel blockers and essential tremor. Eur Neurol 1987,27(2),114-119","journal-title":"Eur Neurol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1212\/WNL.41.2_Part_1.311","volume":"41","author":"Biary N.","year":"1991","unstructured":"Biary N.; al Deeb S.M.; Langenberg P.; The effect of flunarizine on essential tremor. Neurology 1991,41(2 ( Pt 1)),311-312","journal-title":"Neurology"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/00002826-199104000-00005","volume":"14","author":"Gim\u00e9nez-Rold\u00e1n S.","year":"1991","unstructured":"Gim\u00e9nez-Rold\u00e1n S.; Mateo D.; Cinnarizine-induced parkinsonism. Susceptibility related to aging and essential tremor. Clin Neuropharmacol 1991,14(2),156-164","journal-title":"Clin Neuropharmacol"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00002826-199202000-00003","volume":"15","author":"Garc\u00eda-Ruiz P.J.","year":"1992","unstructured":"Garc\u00eda-Ruiz P.J.; Garc\u00eda de Y\u00e9benes J.; Jim\u00e9nez-Jim\u00e9nez F.J.; V\u00e1zquez A.; Garc\u00eda Urra D.; Morales B.; Parkinsonism associated with calcium channel blockers: a prospective follow-up study. Clin Neuropharmacol 1992,15(1),19-26","journal-title":"Clin Neuropharmacol"},{"key":"ref=135","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1212\/WNL.43.1_Part_1.239","volume":"43","author":"Jim\u00e9nez-Jim\u00e9nez F.J.","year":"1993","unstructured":"Jim\u00e9nez-Jim\u00e9nez F.J.; Garc\u00eda-Ruiz P.J.; Flunarizine and essential tremor. Neurology 1993,43(1),239","journal-title":"Neurology"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000117131","volume":"35","author":"Biary N.","year":"1995","unstructured":"Biary N.; al Deeb S.M.; Bahou Y.; Long-term therapy of essential tremor with flunarizine. Eur Neurol 1995,35(4),217-219","journal-title":"Eur Neurol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/00002826-199310000-00011","volume":"16","author":"Curran T.","year":"1993","unstructured":"Curran T.; Lang A.E.; Flunarizine in essential tremor. Clin Neuropharmacol 1993,16(5),460-463","journal-title":"Clin Neuropharmacol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/00002826-199310000-00010","volume":"16","author":"Garc\u00eda Ruiz P.J.","year":"1993","unstructured":"Garc\u00eda Ruiz P.J.; Garc\u00eda de Y\u00e9benes Prous J.; Jim\u00e9nez Jim\u00e9nez J.; Effect of nicardipine on essential tremor: brief report. Clin Neuropharmacol 1993,16(5),456-459","journal-title":"Clin Neuropharmacol"},{"key":"ref=139","first-page":"184","volume":"16","author":"Jim\u00e9nez-Jim\u00e9nez F.J.","year":"1994","unstructured":"Jim\u00e9nez-Jim\u00e9nez F.J.; Garc\u00eda-Ruiz P.J.; Cabrera-Valdivia F.; Nicardipine versus propranolol in essential tumor. Acta Neurol (Napoli) 1994,16(4),184-188","journal-title":"Acta Neurol (Napoli)"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1212\/WNL.45.8.1523","volume":"45","author":"Biary N.","year":"1995","unstructured":"Biary N.; Bahou Y.; Sofi M.A.; Thomas W.; al Deeb S.M.; The effect of nimodipine on essential tremor. Neurology 1995,45(8),1523-1525","journal-title":"Neurology"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejphar.2011.01.004","volume":"659","author":"Quesada A.","year":"2011","unstructured":"Quesada A.; Bui P.H.; Homanics G.E.; Hankinson O.; Handforth A.; Comparison of mibefradil and derivative NNC 55-0396 effects on behavior, cytochrome P450 activity, and tremor in mouse models of essential tremor. Eur J Pharmacol 2011,659(1),30-36","journal-title":"Eur J Pharmacol"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3389\/fneur.2019.00597","volume":"10","author":"Papapetropoulos S.","year":"2019","unstructured":"Papapetropoulos S.; Lee M.S.; Boyer S.; Newbold E.J.; A phase 2, randomized, double-blind, placebo-controlled trial of CX-8998, a selective modulator of the T-Type calcium channel in inadequately treated moderate to severe essential tremor: T-CALM study design and methodology for efficacy endpoint and digital biomarker selection. Front Neurol 2019,10,597","journal-title":"Front Neurol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1212\/WNL.38.2.241","volume":"38","author":"Huber S.J.","year":"1988","unstructured":"Huber S.J.; Paulson G.W.; Efficacy of alprazolam for essential tremor. Neurology 1988,38(2),241-243","journal-title":"Neurology"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s100720070069","volume":"21","author":"Gunal D.I.","year":"2000","unstructured":"Gunal D.I.; Af\u015far N.; Bekiroglu N.; Aktan S.; New alternative agents in essential tremor therapy: double-blind placebo-controlled study of alprazolam and acetazolamide. Neurol Sci 2000,21(5),315-317","journal-title":"Neurol Sci"},{"key":"ref=145","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093159","volume":"9","author":"Ib\u00e1\u00f1ez J.","year":"2014","unstructured":"Ib\u00e1\u00f1ez J.; Gonz\u00e1lez de la Aleja J.; Gallego J.A.; Romero J.P.; Sa\u00edz-D\u00edaz R.A.; Benito-Le\u00f3n J.; Rocon E.; Effects of alprazolam on cortical activity and tremors in patients with essential tremor. PLoS One 2014,9(3)","journal-title":"PLoS One"},{"key":"ref=146","author":"Bruno E.","year":"2015","unstructured":"Bruno E.; Nicoletti A.; Quattrocchi G.; Filippini G.; Zappia M.; Colosimo C.; Alprazolam for essential tremor. Cochrane Database Syst Rev 2015(12)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1212\/WNL.37.3.471","volume":"37","author":"Biary N.","year":"1987","unstructured":"Biary N.; Koller W.; Kinetic predominant essential tremor: successful treatment with clonazepam. Neurology 1987,37(3),471-474","journal-title":"Neurology"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/00002826-198403000-00004","volume":"7","author":"Thompson C.","year":"1984","unstructured":"Thompson C.; Lang A.; Parkes J.D.; Marsden C.D.; A double-blind trial of clonazepam in benign essential tremor. Clin Neuropharmacol 1984,7(1),83-88","journal-title":"Clin Neuropharmacol"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/mds.20940","volume":"21","author":"Martin F.C.","year":"2006","unstructured":"Martin F.C.; Handforth A.; Carbenoxolone and mefloquine suppress tremor in the harmaline mouse model of essential tremor. Mov Disord 2006,21(10),1641-1649","journal-title":"Mov Disord"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s13311-012-0121-1","volume":"9","author":"Nahab F.B.","year":"2012","unstructured":"Nahab F.B.; Handforth A.; Brown T.; Shin C.; Quesada A.; Dong C.; Haubenberger D.; Hallett M.; Octanoic acid suppresses harmaline-induced tremor in mouse model of essential tremor. Neurotherapeutics 2012,9(3),635-638","journal-title":"Neurotherapeutics"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1212\/WNL.62.12.2320","volume":"62","author":"Shill H.A.","year":"2004","unstructured":"Shill H.A.; Bushara K.O.; Mari Z.; Reich M.; Hallett M.; Open-label dose-escalation study of oral 1-octanol in patients with essential tremor. Neurology 2004,62(12),2320-2322","journal-title":"Neurology"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1212\/01.WNL.0000101722.95137.19","volume":"62","author":"Bushara K.O.","year":"2004","unstructured":"Bushara K.O.; Goldstein S.R.; Grimes G.J.; Burstein A.H.; Hallett M.; Pilot trial of 1-octanol in essential tremor. Neurology 2004,62(1),122-124","journal-title":"Neurology"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1172\/JCI83621","volume":"126","author":"Voller B.","year":"2016","unstructured":"Voller B.; Lines E.; McCrossin G.; Tinaz S.; Lungu C.; Grimes G.; Starling J.; Potti G.; Buchwald P.; Haubenberger D.; Hallett M.; Dose-escalation study of octanoic acid in patients with essential tremor. J Clin Invest 2016,126(4),1451-1457","journal-title":"J Clin Invest"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1212\/WNL.0b013e3182840c4f","volume":"80","author":"Haubenberger D.","year":"2013","unstructured":"Haubenberger D.; McCrossin G.; Lungu C.; Considine E.; Toro C.; Nahab F.B.; Auh S.; Buchwald P.; Grimes G.J.; Starling J.; Potti G.; Scheider L.; Kalowitz D.; Bowen D.; Carnie A.; Hallett M.; Octanoic acid in alcohol-responsive essential tremor: a randomized controlled study. Neurology 2013,80(10),933-940","journal-title":"Neurology"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1002\/lary.27695","volume":"129","author":"Lowell S.Y.","year":"2019","unstructured":"Lowell S.Y.; Kelley R.T.; Monahan M.; Hosbach-Cannon C.J.; Colton R.H.; Mihaila D.; The effect of octanoic acid on essential voice tremor: A double-blind, placebo-controlled study. Laryngoscope 2019,129(8),1882-1890","journal-title":"Laryngoscope"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1046\/j.1468-1331.2003.00534.x","volume":"10","author":"Yetimalar Y.","year":"2003","unstructured":"Yetimalar Y.; Irtman G.; G\u00fcrg\u00f6r N.; Ba\u015fo\u011flu M.; Olanzapine efficacy in the treatment of essential tremor. Eur J Neurol 2003,10(1),79-82","journal-title":"Eur J Neurol"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.clineuro.2005.01.002","volume":"108","author":"Yetimalar Y.","year":"2005","unstructured":"Yetimalar Y.; Irtman G.; Kurt T.; Ba\u015fo\u011flu M.; Olanzapine versus propranolol in essential tremor. Clin Neurol Neurosurg 2005,108(1),32-35","journal-title":"Clin Neurol Neurosurg"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1212\/WNL.50.4.1183-a","volume":"50","author":"Jim\u00e9nez-Jim\u00e9nez F.J.","year":"1998","unstructured":"Jim\u00e9nez-Jim\u00e9nez F.J.; Tall\u00f3n-Barranco A.; Ort\u00ed-Pareja M.; Zurdo M.; Porta J.; Molina J.A.; Olanzapine can worsen parkinsonism. Neurology 1998,50(4),1183-1184","journal-title":"Neurology"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1600-0404.1986.tb03279.x","volume":"73","author":"Pakkenberg H.","year":"1986","unstructured":"Pakkenberg H.; Pakkenberg B.; Clozapine in the treatment of tremor. Acta Neurol Scand 1986,73(3),295-297","journal-title":"Acta Neurol Scand"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/00004714-199406000-00015","volume":"14","author":"McCarthy R.H.","year":"1994","unstructured":"McCarthy R.H.; Clozapine reduces essential tremor independent of its antipsychotic effect: a case report. J Clin Psychopharmacol 1994,14(3),212-213","journal-title":"J Clin Psychopharmacol"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/1531-8257(199905)14:3<468:AID-MDS1013>3.0.CO;2-M","volume":"14","author":"Ceravolo R.","year":"1999","unstructured":"Ceravolo R.; Salvetti S.; Piccini P.; Lucetti C.; Gambaccini G.; Bonuccelli U.; Acute and chronic effects of clozapine in essential tremor. Mov Disord 1999,14(3),468-472","journal-title":"Mov Disord"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/00002826-200211000-00004","volume":"25","author":"Micheli F.","year":"2002","unstructured":"Micheli F.; Cers\u00f3simo M.G.; Raina G.; Gatto E.; Quetiapine and essential tremor. Clin Neuropharmacol 2002,25(6),303-306","journal-title":"Clin Neuropharmacol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/ana.410090219","volume":"9","author":"Manyam B.V.","year":"1981","unstructured":"Manyam B.V.; Amantadine in essential tremor. Ann Neurol 1981,9(2),198-199","journal-title":"Ann Neurol"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/ana.410160517","volume":"16","author":"Koller W.C.","year":"1984","unstructured":"Koller W.C.; Amantadine in essential tremor. Ann Neurol 1984,16(5),621-622","journal-title":"Ann Neurol"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/ana.410190125","volume":"19","author":"Obeso J.A.","year":"1986","unstructured":"Obeso J.A.; Luqu\u00edn M.R.; Artieda J.; Mart\u00ednez-Lage J.M.; Amantadine may be useful in essential tremor. Ann Neurol 1986,19(1),99-100","journal-title":"Ann Neurol"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/mds.20676","volume":"21","author":"Gironell A.","year":"2006","unstructured":"Gironell A.; Kulisevsky J.; Pascual-Sedano B.; Flamarich D.; Effect of amantadine in essential tremor: a randomized, placebo-controlled trial. Mov Disord 2006,21(4),441-445","journal-title":"Mov Disord"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/WNF.0b013e31824687bf","volume":"35","author":"Herceg M.","year":"2012","unstructured":"Herceg M.; Nagy F.; P\u00e1l E.; Janszky J.; K\u00e9sm\u00e1rky I.; Komoly S.; Kov\u00e1cs N.; Pramipexole may be an effective treatment option in essential tremor. Clin Neuropharmacol 2012,35(2),73-76","journal-title":"Clin Neuropharmacol"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/cns.12467","volume":"22","author":"Kosmowska B.","year":"2016","unstructured":"Kosmowska B.; Wardas J.; G\u0142owacka U.; Ananthan S.; Ossowska K.; Pramipexole at a low dose induces beneficial effect in the harmaline-induced model of essential tremor in rats. CNS Neurosci Ther 2016,22(1),53-62","journal-title":"CNS Neurosci Ther"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S0025-6196(12)61721-2","volume":"66","author":"Muenter M.D.","year":"1991","unstructured":"Muenter M.D.; Daube J.R.; Caviness J.N.; Miller P.M.; Treatment of essential tremor with methazolamide. Mayo Clin Proc 1991,66(10),991-997","journal-title":"Mayo Clin Proc"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1212\/WNL.42.7.1394","volume":"42","author":"Busenbark K.","year":"1992","unstructured":"Busenbark K.; Pahwa R.; Hubble J.; Koller W.; The effect of acetazolamide on essential tremor: an open-label trial. Neurology 1992,42(7),1394-1395","journal-title":"Neurology"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1212\/WNL.43.5.1045","volume":"43","author":"Busenbark K.","year":"1993","unstructured":"Busenbark K.; Pahwa R.; Hubble J.; Hopfensperger K.; Koller W.; Pogrebra K.; Double-blind controlled study of methazolamide in the treatment of essential tremor. Neurology 1993,43(5),1045-1047","journal-title":"Neurology"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1212\/WNL.47.5.1331","volume":"47","author":"Busenbark K.","year":"1996","unstructured":"Busenbark K.; Ramig L.; Dromey C.; Koller W.C.; Methazolamide for essential voice tremor. Neurology 1996,47(5),1331-1332","journal-title":"Neurology"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/(SICI)1097-4598(199812)21:12<1701:AID-MUS12>3.0.CO;2-K","volume":"21","author":"Modugno N.","year":"1998","unstructured":"Modugno N.; Priori A.; Berardelli A.; Vacca L.; Mercuri B.; Manfredi M.; Botulinum toxin restores presynaptic inhibition of group Ia afferents in patients with essential tremor. Muscle Nerve 1998,21(12),1701-1705","journal-title":"Muscle Nerve"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/mds.870090604","volume":"9","author":"Trosch R.M.","year":"1994","unstructured":"Trosch R.M.; Pullman S.L.; Botulinum toxin A injections for the treatment of hand tremors. Mov Disord 1994,9(6),601-609","journal-title":"Mov Disord"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000117196","volume":"36","author":"Henderson J.M.","year":"1996","unstructured":"Henderson J.M.; Ghika J.A.; Van Melle G.; Haller E.; Einstein R.; Botulinum toxin A in non-dystonic tremors. Eur Neurol 1996,36(1),29-35","journal-title":"Eur Neurol"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/mds.870110306","volume":"11","author":"Jankovic J.","year":"1996","unstructured":"Jankovic J.; Schwartz K.; Clemence W.; Aswad A.; Mordaunt J.; A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord 1996,11(3),250-256","journal-title":"Mov Disord"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/archneur.1996.00550070055012","volume":"53","author":"Pullman S.L.","year":"1996","unstructured":"Pullman S.L.; Greene P.; Fahn S.; Pedersen S.F.; Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients. Arch Neurol 1996,53(7),617-624","journal-title":"Arch Neurol"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s100720070049","volume":"21","author":"Pacchetti C.","year":"2000","unstructured":"Pacchetti C.; Mancini F.; Bulgheroni M.; Zangaglia R.; Cristina S.; Sandrini G.; Nappi G.; Botulinum toxin treatment for functional disability induced by essential tremor. Neurol Sci 2000,21(6),349-353","journal-title":"Neurol Sci"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1212\/WNL.56.11.1523","volume":"56","author":"Brin M.F.","year":"2001","unstructured":"Brin M.F.; Lyons K.E.; Doucette J.; Adler C.H.; Caviness J.N.; Comella C.L.; Dubinsky R.M.; Friedman J.H.; Manyam B.V.; Matsumoto J.Y.; Pullman S.L.; Rajput A.H.; Sethi K.D.; Tanner C.; Koller W.C.; A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 2001,56(11),1523-1528","journal-title":"Neurology"},{"key":"ref=180","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153739","volume":"11","author":"Samotus O.","year":"2016","unstructured":"Samotus O.; Rahimi F.; Lee J.; Jog M.; Functional ability improved in essential tremor by incobotulinumtoxina injections using kinematically determined biomechanical patterns - A new future. PLoS One 2016,11(4)","journal-title":"PLoS One"},{"key":"ref=181","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178670","volume":"12","author":"Samotus O.","year":"2017","unstructured":"Samotus O.; Lee J.; Jog M.; Long-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections. PLoS One 2017,12(6)","journal-title":"PLoS One"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1017\/cjn.2017.260","volume":"45","author":"Samotus O.","year":"2018","unstructured":"Samotus O.; Kumar N.; Rizek P.; Jog M.; Botulinum toxin type a injections as monotherapy for upper limb essential tremor using kinematics. Can J Neurol Sci 2018,45(1),11-22","journal-title":"Can J Neurol Sci"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.parkreldis.2018.06.019","volume":"56","author":"Mittal S.O.","year":"2018","unstructured":"Mittal S.O.; Machado D.; Richardson D.; Dubey D.; Jabbari B.; Botulinum toxin in essential hand tremor - A randomized double-blind placebo-controlled study with customized injection approach. Parkinsonism Relat Disord 2018,56,65-69","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=184","doi-asserted-by":"publisher","DOI":"10.3390\/toxins10070299","author":"Niemann N.","unstructured":"Niemann N.; Jankovic J.; Botulinum toxin for the treatment of hand tremor Toxins (Basel), 2018, 10(7), pii, E299","journal-title":"Botulinum toxin for the treatment of hand tremor Toxins (Basel), 2018, 10(7), pii, E299"},{"key":"ref=185","doi-asserted-by":"publisher","DOI":"10.3390\/toxins11020125","author":"Samotus O.","unstructured":"Samotus O.; Lee J.; Jog M.; Personalized bilateral upper limb essential tremor therapy with botulinum toxin using kinematics Toxins (Basel), 2019, 11(2), pii, E125","journal-title":"Personalized bilateral upper limb essential tremor therapy with botulinum toxin using kinematics Toxins (Basel), 2019, 11(2), pii, E125"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1212\/WNL.45.4.822","volume":"45","author":"Pahwa R.","year":"1995","unstructured":"Pahwa R.; Busenbark K.; Swanson-Hyland E.F.; Dubinsky R.M.; Hubble J.P.; Gray C.; Koller W.C.; Botulinum toxin treatment of essential head tremor. Neurology 1995,45(4),822-824","journal-title":"Neurology"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/mds.870120516","volume":"12","author":"Wissel J.","year":"1997","unstructured":"Wissel J.; Masuhr F.; Schelosky L.; Ebersbach G.; Poewe W.; Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Mov Disord 1997,12(5),722-726","journal-title":"Mov Disord"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1097\/00005537-200008000-00028","volume":"110","author":"Warrick P.","year":"2000","unstructured":"Warrick P.; Dromey C.; Irish J.C.; Durkin L.; Pakiam A.; Lang A.; Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection. Laryngoscope 2000,110(8),1366-1374","journal-title":"Laryngoscope"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1177\/000348940010900216","volume":"109","author":"Herteg\u00e5rd S.","year":"2000","unstructured":"Herteg\u00e5rd S.; Granqvist S.; Lindestad P.A.; Botulinum toxin injections for essential voice tremor. Ann Otol Rhinol Laryngol 2000,109(2),204-209","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1001\/archneur.61.9.1416","volume":"61","author":"Adler C.H.","year":"2004","unstructured":"Adler C.H.; Bansberg S.F.; Hentz J.G.; Ramig L.O.; Buder E.H.; Witt K.; Edwards B.W.; Krein-Jones K.; Caviness J.N.; Botulinum toxin type A for treating voice tremor. Arch Neurol 2004,61(9),1416-1420","journal-title":"Arch Neurol"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/lary.25485","volume":"126","author":"Justicz N.","year":"2016","unstructured":"Justicz N.; Hapner E.R.; Josephs J.S.; Boone B.C.; Jinnah H.A.; Johns M.M.; Comparative effectiveness of propranolol and botulinum for the treatment of essential voice tremor. Laryngoscope 2016,126(1),113-117","journal-title":"Laryngoscope"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/lary.26911","volume":"128","author":"Estes C.","year":"2018","unstructured":"Estes C.; Sadoughi B.; Coleman R.; Sarva H.; Mauer E.; Sulica L.; A prospective crossover trial of botulinum toxin chemodenervation versus injection augmentation for essential voice tremor. Laryngoscope 2018,128(2),437-446","journal-title":"Laryngoscope"},{"key":"ref=193","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2018\/e87","volume":"73","author":"Guglielmino G.","year":"2018","unstructured":"Guglielmino G.; Moraes B.T.; Villanova L.C.; Padovani M.; Biase N.G.; Comparison of botulinum toxin and propranolol for essential and dystonic vocal tremors. Clinics (S\u00e3o Paulo) 2018,73","journal-title":"Clinics (S\u00e3o Paulo)"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/088307389300800208","volume":"8","author":"Gordon K.","year":"1993","unstructured":"Gordon K.; Cadera W.; Hinton G.; Successful treatment of hereditary trembling chin with botulinum toxin. J Child Neurol 1993,8(2),154-156","journal-title":"J Child Neurol"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/mds.870130516","volume":"13","author":"Bakar M.","year":"1998","unstructured":"Bakar M.; Zarifoglu M.; Bora I.; Turan F.; Sen C.; Ogul E.; Treatment of hereditary trembling chin with botulinum toxin. Mov Disord 1998,13(5),845-846","journal-title":"Mov Disord"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/mds.20878","volume":"21","author":"Gonzalez-Alegre P.","year":"2006","unstructured":"Gonzalez-Alegre P.; Kelkar P.; Rodnitzky R.L.; Isolated high-frequency jaw tremor relieved by botulinum toxin injections. Mov Disord 2006,21(7),1049-1050","journal-title":"Mov Disord"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/mds.1132","volume":"16","author":"Cho J.W.","year":"2001","unstructured":"Cho J.W.; Chu K.; Jeon B.S.; Case of essential palatal tremor: atypical features and remarkable benefit from botulinum toxin injection. Mov Disord 2001,16(4),779-782","journal-title":"Mov Disord"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s00415-006-0039-9","volume":"253","author":"Penney S.E.","year":"2006","unstructured":"Penney S.E.; Bruce I.A.; Saeed S.R.; Botulinum toxin is effective and safe for palatal tremor: a report of five cases and a review of the literature. J Neurol 2006,253(7),857-860","journal-title":"J Neurol"},{"key":"ref=199","first-page":"697","volume":"15","author":"Simpson D.M.","year":"2008","unstructured":"Simpson D.M.; Blitzer A.; Brashear A.; Comella C.; Dubinsky R.; Hallett M.; Jankovic J.; Karp B.; Ludlow C.L.; Miyasaki J.M.; Naumann M.; So Y.; Assesment, Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review), report of the Therapeutics and Technology Assesment Subcommittee of the American Academy of Neurology. Neurology 2008,15,697-705","journal-title":"Neurology"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/cns.12692","volume":"23","author":"Kosmowska B.","year":"2017","unstructured":"Kosmowska B.; Ossowska K.; G\u0142owacka U.; Wardas J.; Tremorolytic effect of 5\u2032-chloro-5\u2032-deoxy-(\u00b1)-ENBA, a potent and selective adenosine A1 receptor agonist, evaluated in the harmaline-induced model in rats. CNS Neurosci Ther 2017,23(5),438-446","journal-title":"CNS Neurosci Ther"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0022-510X(95)00128-O","volume":"132","author":"Mally J.","year":"1995","unstructured":"Mally J.; Stone T.W.; Efficacy of an adenosine antagonist, theophylline, in essential tremor: comparison with placebo and propranolol. J Neurol Sci 1995,132(2),129-132","journal-title":"J Neurol Sci"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1365-2125.1997.tb00044.x","volume":"43","author":"Buss D.C.","year":"1997","unstructured":"Buss D.C.; Marshall R.W.; Milligan N.; McQueen I.; Compston D.A.; Routledge P.A.; The effect of intravenous aminophylline on essential tremor. Br J Clin Pharmacol 1997,43(1),119-121","journal-title":"Br J Clin Pharmacol"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejphar.2012.08.014","volume":"695","author":"Rahimi Shourmasti F.","year":"2012","unstructured":"Rahimi Shourmasti F.; Goudarzi I.; Lashkarbolouki T.; Abrari K.; Elahdadi Salmani M.; Goudarzi A.; Effects of riluzole on harmaline induced tremor and ataxia in rats: biochemical, histological and behavioral studies. Eur J Pharmacol 2012,695(1-3),40-47","journal-title":"Eur J Pharmacol"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.neuropharm.2011.05.015","volume":"61","author":"Iseri P.K.","year":"2011","unstructured":"Iseri P.K.; Karson A.; Gullu K.M.; Akman O.; Kokturk S.; Yard\u00fdmoglu M.; Erturk S.; Ates N.; The effect of memantine in harmaline-induced tremor and neurodegeneration. Neuropharmacology 2011,61(4),715-723","journal-title":"Neuropharmacology"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.neulet.2015.01.078","volume":"590","author":"Vaziri Z.","year":"2015","unstructured":"Vaziri Z.; Abbassian H.; Sheibani V.; Haghani M.; Nazeri M.; Aghaei I.; Shabani M.; The therapeutic potential of Berberine chloride hydrate against harmaline-induced motor impairments in a rat model of tremor. Neurosci Lett 2015,590,84-90","journal-title":"Neurosci Lett"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/WNF.0b013e3181ebd109","volume":"33","author":"Handforth A.","year":"2010","unstructured":"Handforth A.; Bordelon Y.; Frucht S.J.; Quesada A.; A pilot efficacy and tolerability trial of memantine for essential tremor. Clin Neuropharmacol 2010,33(5),223-226","journal-title":"Clin Neuropharmacol"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1212\/WNL.53.5.1154-a","volume":"53","author":"Pact V.","year":"1999","unstructured":"Pact V.; Giduz T.; Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology 1999,53(5),1154","journal-title":"Neurology"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/mds.10371","volume":"18","author":"Pahwa R.","year":"2003","unstructured":"Pahwa R.; Lyons K.E.; Mirtazapine in essential tremor: a double-blind, placebo-controlled pilot study. Mov Disord 2003,18(5),584-587","journal-title":"Mov Disord"},{"key":"ref=209","first-page":"95","volume":"2","author":"Uccellini D.","year":"2006","unstructured":"Uccellini D.; Grampa G.; La Spina I.; Nasuelli D.; Neromante I.; Politini L.; Reverberi F.; Porazzi D.; Carli V.; Camardese G.; Mirtazapine in the treatment of essential tremor: an open-label, observer-blind study. Neuropsychiatr Dis Treat 2006,2(1),95-100","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/00002826-198904000-00009","volume":"12","author":"Koller W.C.","year":"1989","unstructured":"Koller W.C.; Tradozone in essential tremor. Probe of serotoninergic mechanisms. Clin Neuropharmacol 1989,12(2),134-137","journal-title":"Clin Neuropharmacol"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1001\/jama.1986.03380190045017","volume":"256","author":"McLeod N.A.","year":"1986","unstructured":"McLeod N.A.; White L.E.; Trazodone in essential tremor. JAMA 1986,256(19),2675-2676","journal-title":"JAMA"},{"key":"ref=212","first-page":"358","volume":"56","author":"Sanson F.","year":"1986","unstructured":"Sanson F.; Schergna E.; Semenzato D.; Trevisan C.P.; Bizzarini M.; Violante F.; Santagostino I.; Ravenna C.; Maccarone G.; Effetti terapeutici del Trazodone nel trattamento del tremore. Studio policentrico in doppio cieco. Riv Neurol 1986,56(6),358-364","journal-title":"Riv Neurol"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1136\/jnnp.53.3.268-a","volume":"53","author":"Cleeves L.","year":"1990","unstructured":"Cleeves L.; Findley L.J.; Trazodone is ineffective in essential tremor. J Neurol Neurosurg Psychiatry 1990,53(3),268-269","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1600-0404.1989.tb03804.x","volume":"79","author":"Caccia M.R.","year":"1989","unstructured":"Caccia M.R.; Osio M.; Galimberti V.; Cataldi G.; Mangoni A.; Propranolol, clonidine, urapidil and trazodone infusion in essential tremor: a double-blind crossover trial. Acta Neurol Scand 1989,79(5),379-383","journal-title":"Acta Neurol Scand"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0140-6736(71)92340-3","volume":"2","author":"Morris C.E.","year":"1971","unstructured":"Morris C.E.; Prange A.J.; Hall C.D.; Weissm E.A.; Inefficacy of tryptophan\/piridoxine in essential tremor. Lancet 1971,2,165-166","journal-title":"Lancet"},{"key":"ref=216","first-page":"251","volume":"13","author":"Guillard A.","year":"1979","unstructured":"Guillard A.; Chastang C.; Application of 5 HTP in the treatment of essential tremor. Int J Neurol 1979,13(1-4),251-253","journal-title":"Int J Neurol"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/BF00314043","volume":"232","author":"Caccia M.R.","year":"1985","unstructured":"Caccia M.R.; Mangoni A.; Clonidine in essential tremor: preliminary observations from an open trial. J Neurol 1985,232(1),55-57","journal-title":"J Neurol"},{"key":"ref=218","first-page":"9","volume":"12","author":"Serrano Due\u00f1as M.","year":"1997","unstructured":"Serrano Due\u00f1as M.; Prueba farmacol\u00f3gica aguda con clonidina en el temblor esencial. Neurologia 1997,12(1),9-11","journal-title":"Neurologia"},{"key":"ref=219","first-page":"248","volume":"18","author":"Serrano-Due\u00f1as M.","year":"2003","unstructured":"Serrano-Due\u00f1as M.; Clonidina frente a propanolol en el tratamiento del temblor esencial. Estudio doble ciego con un a\u00f1o de seguimiento. Neurologia 2003,18(5),248-254","journal-title":"Neurologia"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/mds.870010403","volume":"1","author":"Koller W.","year":"1986","unstructured":"Koller W.; Herbster G.; Cone S.; Clonidine in the treatment of essential tremor. Mov Disord 1986,1(4),235-237","journal-title":"Mov Disord"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/jnnp.44.12.1171","volume":"44","author":"Mai J.","year":"1981","unstructured":"Mai J.; Olsen R.B.; Depression of essential tremor by alpha-adrenergic blockade. J Neurol Neurosurg Psychiatry 1981,44(12),1171","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/jnnp.49.2.222-a","volume":"49","author":"Koller W.C.","year":"1986","unstructured":"Koller W.C.; Ineffectiveness of phenoxybenzamine in essential tremor. J Neurol Neurosurg Psychiatry 1986,49(2),222","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1002\/mds.20605","volume":"20","author":"Frucht S.J.","year":"2005","unstructured":"Frucht S.J.; Bordelon Y.; Houghton W.H.; Reardan D.; A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders. Mov Disord 2005,20(10),1330-1337","journal-title":"Mov Disord"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1212\/01.wnl.0000188670.38576.bd","volume":"65","author":"Frucht S.J.","year":"2005","unstructured":"Frucht S.J.; Houghton W.C.; Bordelon Y.; Greene P.E.; Louis E.D.; A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor. Neurology 2005,65(12),1967-1969","journal-title":"Neurology"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/mds.870040110","volume":"4","author":"McDowell F.H.","year":"1989","unstructured":"McDowell F.H.; The use of glutethimide for treatment of essential tremor. Mov Disord 1989,4(1),75-80","journal-title":"Mov Disord"},{"key":"ref=226","first-page":"369","volume":"32","author":"Pozos R.S.","year":"1992","unstructured":"Pozos R.S.; Iaizzo P.A.; Effects of topical anesthesia on essential tremor. Electromyogr Clin Neurophysiol 1992,32(7-8),369-372","journal-title":"Electromyogr Clin Neurophysiol"},{"key":"ref=227","first-page":"83","volume":"40","author":"Ishizaki F.","year":"1991","unstructured":"Ishizaki F.; Harada T.; Kito S.; Harada A.; Saeki M.; Nakamura S.; The effect of bovine brain gangliosides on essential tremor. Hiroshima J Med Sci 1991,40(2),83-85","journal-title":"Hiroshima J Med Sci"},{"key":"ref=228","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-223945","author":"Costantini A.","unstructured":"Costantini A.; High-dose thiamine and essential tremor BMJ Case Rep, 2018; pii, bcr-2017-223945","journal-title":"High-dose thiamine and essential tremor BMJ Case Rep, 2018; pii, bcr-2017-223945"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1001\/archneur.1987.00520210007009","volume":"44","author":"Koller W.C.","year":"1987","unstructured":"Koller W.C.; Rubino F.; Gupta S.; Pharmacologic probe with progabide of GABA mechanisms in essential tremor. Arch Neurol 1987,44(9),905-906","journal-title":"Arch Neurol"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1600-0404.1983.tb04833.x","volume":"68","author":"Mondrup K.","year":"1983","unstructured":"Mondrup K.; Dupont E.; Pedersen E.; The effect of the GABA-agonist, progabide, on benign essential tremor. A controlled clinical trial. Acta Neurol Scand 1983,68(4),248-252","journal-title":"Acta Neurol Scand"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/mds.870060310","volume":"6","author":"Hallett M.","year":"1991","unstructured":"Hallett M.; Ravits J.; Dubinsky R.M.; Gillespie M.M.; Moinfar A.; A double-blind trial of isoniazid for essential tremor and other action tremors. Mov Disord 1991,6(3),253-256","journal-title":"Mov Disord"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/jnnp.49.2.198","volume":"49","author":"Ter\u00e4v\u00e4inen H.","year":"1986","unstructured":"Ter\u00e4v\u00e4inen H.; Huttunen J.; Lewitt P.; Ineffective treatment of essential tremor with an alcohol, methylpentynol. J Neurol Neurosurg Psychiatry 1986,49(2),198-199","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1212\/01.wnl.0000218297.90054.28","volume":"66","author":"Lorenz D.","year":"2006","unstructured":"Lorenz D.; Hagen K.; Ufer M.; Cascorbi I.; Deuschl G.; Volkmann J.; No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study. Neurology 2006,66(11),1753-1755","journal-title":"Neurology"},{"key":"ref=234","first-page":"7810","volume":"60","author":"Handforth A.","year":"2018","unstructured":"Handforth A.; Kadam P.A.; Kosoyan H.P.; Eslami P.; Neuroactive steroids. 2. 3\u03b1-Hydroxy-3\u03b2-methyl-21-(4-cyano-1H-pyrazol-1\u2032-yl)-19-nor-5\u03b2-pregnan-20-one (SAGE-217), a clinical next generation neuroactive steroid positive allosteric modulator of the (\u03b3-Aminobutyric acid) A receptor. J Med Chem 2018,60,7810-7819","journal-title":"J Med Chem"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0304-3940(01)02166-8","volume":"312","author":"Tariq M.","year":"2001","unstructured":"Tariq M.; Arshaduddin M.; Biary N.; Al Moutaery K.; Al Deeb S.; Baclofen attenuates harmaline induced tremors in rats. Neurosci Lett 2001,312(2),79-82","journal-title":"Neurosci Lett"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"7810","DOI":"10.1021\/acs.jmedchem.7b00846","volume":"60","author":"Martinez Botella G.","year":"2017","unstructured":"Martinez Botella G.; Salituro F.G.; Harrison B.L.; Beresis R.T.; Bai Z.; Blanco M.J.; Belfort G.M.; Dai J.; Loya C.M.; Ackley M.A.; Althaus A.L.; Grossman S.J.; Hoffmann E.; Doherty J.J.; Robichaud A.J.; Neuroactive steroids. 2. 3\u03b1-hydroxy-3\u03b2-methyl-21-(4-cyano-1H-pyrazol-1\u2032-yl)-19-nor-5\u03b2-pregnan-20-one (SAGE-217): A clinical next generation neuroactive steroid positive allosteric modulator of the (\u03b3-Aminobutyric acid) receptor. J Med Chem 2017,60(18),7810-7819","journal-title":"J Med Chem"},{"key":"ref=237","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.wneu.2017.05.112","volume":"105","author":"Hamad M.","year":"2017","unstructured":"Hamad M.; Holland R.; Kamal N.; Luceri R.; Mammis A.; Potential for intrathecal baclofen in treatment of essential tremor. World Neurosurg 2017,105,170-175","journal-title":"World Neurosurg"},{"key":"ref=238","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.neulet.2019.04.017","volume":"704","author":"Mohammadi F.","year":"2019","unstructured":"Mohammadi F.; Abedini Esfahlani M.; Shabani M.; Erythropoietin ameliorates harmaline-induced essential tremor and cognition disturbances. Neurosci Lett 2019,704,153-158","journal-title":"Neurosci Lett"},{"key":"ref=239","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.neulet.2017.06.015","volume":"653","author":"Dahmardeh N.","year":"2017","unstructured":"Dahmardeh N.; Asadi-Shekaari M.; Arjmand S.; Kalantaripour T.; Basiri M.; Shabani M.; Modulation of sphingosine-1-phosphate receptor ameliorates harmaline-induced essential tremor in rat. Neurosci Lett 2017,653,376-381","journal-title":"Neurosci Lett"},{"key":"ref=240","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1080\/01616412.2016.1275456","volume":"39","author":"Abdulrahman A.A.","year":"2017","unstructured":"Abdulrahman A.A.; Faisal K.; Meshref A.A.; Arshaduddin M.; Low-dose acute vanillin is beneficial against harmaline-induced tremors in rats. Neurol Res 2017,39(3),264-270","journal-title":"Neurol Res"},{"key":"ref=241","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1111\/bph.13581","volume":"173","author":"Abbassian H.","year":"2016","unstructured":"Abbassian H.; Whalley B.J.; Sheibani V.; Shabani M.; Cannabinoid type 1 receptor antagonism ameliorates harmaline-induced essential tremor in rat. Br J Pharmacol 2016,173(22),3196-3207","journal-title":"Br J Pharmacol"},{"key":"ref=242","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1517\/14728222.2015.1028360","volume":"19","author":"Ag\u00fandez J.A.","year":"2015","unstructured":"Ag\u00fandez J.A.; Jim\u00e9nez-Jimenez F.J.; Alonso-Navarro H.; Garc\u00eda-Mart\u00edn E.; The potential of LINGO-1 as a therapeutic target for essential tremor. Expert Opin Ther Targets 2015,19(8),1139-1148","journal-title":"Expert Opin Ther Targets"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/178616","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T20:07:33Z","timestamp":1614110853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/178616\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,22]]},"references-count":242,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6,22]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x18666200124145743","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,22]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-08-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}